Insilico teams up with Boehringer Ingelheim on drug discovery

Research collaboration to apply generative AI system for discovery of potential therapeutic targets.

Artificial intelligence company Insilico Medicine has announced a research collaboration with pharmaceutical giant Boehringer Ingelheim. The companies will work together to identify potential therapeutic targets implicated in a variety of diseases using Insilico’s generative machine learning technology and its Pandomics Discovery Platform.
The Pandomics platform enables the development of comprehensive disease profiles that can be analysed for drug discovery and biomarker development, providing data on the highest scoring molecules and targets.

“Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets,” said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine. “In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group.”


“In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide…”


Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies with net sales of around $19 billion in 2018.

“We believe that Insilico’s exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets,” said Dr. Weiyi Zhang, Head of External Innovation Hub, Boehringer Ingelheim Greater China. “We look forward to using AI to significantly improve the drug discovery process and contribute to human health.”

In January, Insilico Medicine announced a collaboration with skin care firm Beiersdorf to discover bioactive ingredients for skin indications.

Image credit: Tada Images / Shutterstock

No spam - just the good stuff

Subscribe to our newsletter